<DOC>
	<DOCNO>NCT00193089</DOCNO>
	<brief_summary>In phase II trial attempt improve upon efficacy trastuzumab/vinorelbine combination add weekly docetaxel . When administered weekly schedule , docetaxel well tolerate minimal myelosuppression , likely fully efficacious dos three drug administer</brief_summary>
	<brief_title>Docetaxel , Vinorelbine Trastuzumab Treatment Patients With Metastatic Her-2 Positive Breast Cancer</brief_title>
	<detailed_description>Upon determination eligibility , patient receive : Trastuzumab + Vinorelbine + Docetaxel</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>To include study , must meet following criterion : Metastatic breast cancer confirm biopsy Overexpression Her2 oncogene Age &gt; 18 year Measurable disease Able perform activity daily live minimal assistance No previous chemotherapy metastatic disease One previous hormonal therapy metastatic disease . Adequate bone marrow , liver kidney function Patients &lt; grade 1 peripheral neuropathy eligible . Must give write informed consent prior enter study . You participate study follow apply : Abnormal heart function Previous treatment trastuzumab Brain metastasis untreated Preexisting symptomatic peripheral neuropathy Serious underlie medical condition Please note : There additional inclusion/exclusion criterion . The study center determine meet criterion . If qualify trial , study personnel explain reason . If qualify , study personnel explain trial detail answer question may .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>